Blume Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-55
| Closed | -$1.66K | – | 498 |
|
|
2025
Q1 | $1.66K | Hold |
55
| – | – | ﹤0.01% | 345 |
|
|
2024
Q4 | $1.92K | Hold |
55
| – | – | ﹤0.01% | 306 |
|
|
2024
Q3 | $2.2K | Hold |
55
| – | – | ﹤0.01% | 327 |
|
|
2024
Q2 | $2.62K | Hold |
55
| – | – | ﹤0.01% | 293 |
|
|
2024
Q1 | $2.38K | Hold |
55
| – | – | ﹤0.01% | 291 |
|
|
2023
Q4 | $2.78K | Hold |
55
| – | – | ﹤0.01% | 290 |
|
|
2023
Q3 | $2.5K | Hold |
55
| – | – | ﹤0.01% | 290 |
|
|
2023
Q2 | $2.26K | Hold |
55
| – | – | ﹤0.01% | 295 |
|
|
2023
Q1 | $1.97K | Hold |
55
| – | – | ﹤0.01% | 288 |
|
|
2022
Q4 | $2.08K | Hold |
55
| – | – | ﹤0.01% | 294 |
|
|
2022
Q3 | $2K | Hold |
55
| – | – | ﹤0.01% | 295 |
|
|
2022
Q2 | $2K | Hold |
55
| – | – | ﹤0.01% | 297 |
|
|
2022
Q1 | $2K | Hold |
55
| – | – | ﹤0.01% | 304 |
|
|
2021
Q4 | $2K | Sell |
55
-35
| -39% | -$1.1K | ﹤0.01% | 293 |
|
|
2021
Q3 | $3K | Hold |
90
| – | – | ﹤0.01% | 288 |
|
|
2021
Q2 | $4K | Hold |
90
| – | – | ﹤0.01% | 263 |
|
|
2021
Q1 | $4K | Hold |
90
| – | – | ﹤0.01% | 246 |
|
|
2020
Q4 | $5K | Hold |
90
| – | – | ﹤0.01% | 204 |
|
|
2020
Q3 | $4K | Hold |
90
| – | – | ﹤0.01% | 200 |
|
|
2020
Q2 | $5K | Hold |
90
| – | – | ﹤0.01% | 192 |
|
|
2020
Q1 | $4K | Hold |
90
| – | – | ﹤0.01% | 216 |
|
|
2019
Q4 | $5K | Hold |
90
| – | – | ﹤0.01% | 211 |
|
|
2019
Q3 | $5K | Hold |
90
| – | – | ﹤0.01% | 211 |
|
|
2019
Q2 | $6K | Hold |
90
| – | – | ﹤0.01% | 194 |
|
|
2019
Q1 | $7K | Hold |
90
| – | – | ﹤0.01% | 198 |
|
|
2018
Q4 | $5K | Hold |
90
| – | – | ﹤0.01% | 204 |
|
|
2018
Q3 | $5K | Hold |
90
| – | – | ﹤0.01% | 180 |
|
|
2018
Q2 | $4K | Hold |
90
| – | – | ﹤0.01% | 179 |
|
|
2018
Q1 | $3K | Hold |
90
| – | – | ﹤0.01% | 200 |
|
|
2017
Q4 | $5K | Hold |
90
| – | – | ﹤0.01% | 201 |
|
|
2017
Q3 | $5K | Hold |
90
| – | – | ﹤0.01% | 216 |
|
|
2017
Q2 | $5K | Hold |
90
| – | – | ﹤0.01% | 182 |
|
|
2017
Q1 | $4K | Hold |
90
| – | – | ﹤0.01% | 183 |
|
|
2016
Q4 | $4K | Hold |
90
| – | – | ﹤0.01% | 187 |
|
|
2016
Q3 | $3K | Hold |
90
| – | – | ﹤0.01% | 182 |
|
|
2016
Q2 | $2K | Hold |
90
| – | – | ﹤0.01% | 205 |
|
|
2016
Q1 | $4K | Hold |
90
| – | – | ﹤0.01% | 215 |
|
|
2015
Q4 | $6K | Hold |
90
| – | – | ﹤0.01% | 203 |
|
|
2015
Q3 | $4K | Hold |
90
| – | – | ﹤0.01% | 212 |
|
|
2015
Q2 | $5K | Hold |
90
| – | – | ﹤0.01% | 207 |
|
|
2015
Q1 | $6K | Hold |
90
| – | – | ﹤0.01% | 250 |
|
|
2014
Q4 | $6K | Hold |
90
| – | – | ﹤0.01% | 264 |
|
|
2014
Q3 | $3K | Hold |
90
| – | – | ﹤0.01% | 181 |
|
|
2014
Q2 | $3K | Buy |
+90
| New | +$2.83K | ﹤0.01% | 199 |
|
Other funds holding IONS
BG
DTC
Blume Capital Management's IONS Position: Q2 2025 in Review
Blume Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 55 shares — an estimated $1.66K sold.
Blume Capital Management first reported a position in IONS in Q2 2014 and held it in 44 quarters. The position peaked at $7K in Q1 2019. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.
- Blume Capital Management reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Blume Capital Management sold 55 Ionis Pharmaceuticals shares in Q2 2025, an estimated $1.66K.
- Blume Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 44 quarters.
- Blume Capital Management's Ionis Pharmaceuticals position peaked at $7K in Q1 2019.
- 362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.
Based on Blume Capital Management's 13F filing for Q2 2025, filed 30 Jul 2025.